Aquestive Therapeutics Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Aquestive Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $8.89. The average 1-year stock price forecast is 122.81% higher than the current stock price, while the lowest is $6.00 (+50.38%) and the highest is $11 (+175.69%).

Price Target: $8.89 (+122.81%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$6.00	$8.89	$9.00	$11
Change	+50.38%	+122.81%	+125.56%	+175.69%

Analyst Ratings

The average analyst rating for Aquestive Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	7	7	7	7	7	7
Buy	2	1	2	2	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	9	8	9	9	9	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Roanna Ruiz Leerink Partners	Leerink Partners	Buy Reiterates $9	Buy	Reiterates	$9	+125.56%	May 15, 2026
Francois Brisebois LifeSci Capital	LifeSci Capital	Buy Reiterates $9	Buy	Reiterates	$9	+125.56%	May 15, 2026
Thomas Flaten Lake Street	Lake Street	Buy Maintains $6	Buy	Maintains	$6	+50.38%	May 15, 2026
Andreas Argyrides Oppenheimer	Oppenheimer	Buy Reiterates $8	Buy	Reiterates	$8	+100.50%	May 15, 2026
David Amsellem Piper Sandler	Piper Sandler	Buy Reiterates $8	Buy	Reiterates	$8	+100.50%	May 15, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

50.52M

from 44.55M

13.40%

from 44.55M

Revenue Next Year

71.91M

from 50.52M

42.36%

from 50.52M

EPS This Year

-0.42

from -0.59

EPS Next Year

-0.45

from -0.42

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	50.83M	47.68M	50.58M	57.56M	44.55M	50.52M
Revenue Growth	10.87%	-6.20%	6.09%	13.79%	-22.61%	13.40%
Gross Profit	35.84M	28.29M	29.75M	39.69M	25.99M	33.42M
Gross Margin	70.51%	59.34%	58.82%	68.95%	58.35%	66.15%
Operating Income	-34.68M	-42.07M	-15.10M	-30.77M	-71.05M	-37.82M
Net Income	-70.54M	-54.41M	-7.87M	-44.14M	-83.78M	-50.65M
EPS	-	-	-	-	-0.59	-0.42
Free Cash Flow	-28.10M	-21.29M	-16.22M	-10.49M	-29.24M	-15.00M
No. Analysts	-	-	-	-	-	9

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	55.3M
Avg	50.5M
Low	47.4M

Revenue Growth

Revenue Growth	2026	2027	2028
High	24.2%
Avg	13.4%
Low	6.5%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.42
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-